Pharmaceuticals
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
* The confirmed objective response (cORR), as assessed by blinded independent central review (BICR), was 59.8% in advanced NSCLC with EGFR exon20ins mutations after at least one line of platinum-based chemotherapies * The response rate for patients with baseline brain metastasis was 48.4% * ...
Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO
PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data from the global Phase I study ofDZD1516 in patients with HER2 positive metastatic breast cancer (HER2+ MBC) who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncolo...
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives
CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. ("Unison") are pleased to announce a research collaboration on an undisclosed bacterial target. Under the terms of the agreement, Vernalis will use it...
Thailand heightens its healthcare hub ambition with integrative medicine
BANGKOK, Sept. 5, 2022 /PRNewswire/ -- Living with the COVID-19 pandemic, people start to recognize the equal importance of modern medicine and preventive practices in maintaining their good health and wellbeing. With a strong healthcare and wellness infrastructure and reputation for highly-skill...
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As ofJune 30, Simcere recorded operating revenue of RMB 2.7 billion for the first half of the year, with a year-over-year growth of 27.3%. The e...
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group announces today the appointment ofTamas Oravecz, Ph.D. as Senior Vice President, Chief Scientific Officer of the Simcere U.S. Tamas will be responsible for providing strategic leadership to our drug discovery efforts in A...
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
- CornerStone-001(NCT05163223), the multiregional clinical trial for breast cancer treatment, received U.S. FDA approval for Phase 2 trial following the approvals inAustralia and the Taiwan region. - As the same patient group and design of a pivotal study are adopted, a placebo-controlled randomi...
LEADERS IN NUTRITIONAL MEDICINE ON CUSP OF BREAKTHROUGH GUIDELINES TO TACKLE LONG-COVID SYMPTOMS
Guidelines for health practitioner diagnosis of Long-COVID are in review Understanding of mitochondrial health integral to post-pandemic recovery, say experts Ninety per cent of people hospitalised with COVID-19 have significant underlying medical conditions, and are more likely to develop Long ...
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
BEIJING, Sept. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed first patient dosage of it's in-house R&D drug candidate CD73 monoclonal antibody JAB-BX102 in a Phase I/IIa clinical trial for advanced solid tumour patients. This is a phase I/IIa multi-center, open-la...
Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022
* Non-clinical studies explored the potent anti-fibrotic and anti-inflammatory efficacy of BBT-301 and BBT-209 for IPF treatment * Company enhances its strategic focus on fibrotic diseases inclusive of IPF with 1 clinical asset and 2 non-clinical assets BOSTON and SEONGNAM, South Korea ,Sept. ...
Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management
SHANGHAI, Sept 1, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today a...
Cambrex Completes First Phase of $30 Million Capacity Expansion Project in High Point, North Carolina
EAST RUTHERFORD, NJ, Sept. 1, 2022 /PRNewswire/ -- Cambrex today announced the completion of the first phase of its$30 million investment in its small molecule active pharmaceutical ingredient (API) manufacturing facility inHigh Point, North Carolina. The newly constructed space adds analytical a...
Juniper Biologics Pte. Ltd. signs exclusive license agreement with Helsinn Healthcare SA for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*
LUGANO, Switzerland, Sept. 1, 2022 /PRNewswire/ -- Helsinn Group ("Helsinn"), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Juniper Biologics Pte Ltd, a science-led healthcare company foc...
"Blue Pea Flower and Banana Stem Extract" Drink to Reduce the Risk of Urinary Stone - Another Medical Innovation from Chula MED
BANGKOK, Sept. 1, 2022 /PRNewswire/ -- Urinary tract stone is common among
people of the tropics such asThailand. In 2020, surveys show that 16-17 percent
of the population have this disease, and up to 12 percent of the patients have
an asymptomatic urinary stone.
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
Addition increases diversity of Board governance and supports further
independent expertise
DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences
Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet pat...
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. held a signing ceremony with Phil. Pharmawealth, Inc. for their cooperation in jointly promoting th...
NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
TAIPEI, Aug. 31, 2022 /PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of NIH. The purpose of this study is to asses...
GC Biopharma and Speragen Sponsored an Externally Led - Patient Focused Drug Development with FDA Attendance
YONGIN, South Korea and AUSTIN, Texas, Aug. 30 2022 /PRNewswire/ -- GC Biopharma (006280.KS) and Speragen today announced that a joint Externally Led - Patient-Focused Drug Development (EL-PFDD) meeting hosted by SSADH Association and attended by the U.S. FDA and other stakeholders was held to a...
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07